Details for Patent: 10,278,974
✉ Email this page to a colleague
Which drugs does patent 10,278,974 protect, and when does it expire?
Patent 10,278,974 protects RUBRACA and is included in one NDA.
This patent has sixty-six patent family members in thirty-one countries.
Summary for Patent: 10,278,974
| Title: | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[- 5,4,3-cd]indol-6-one |
| Abstract: | The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[- 5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer. |
| Inventor(s): | Basford; Patricia Ann (Sandwich, GB), Campeta; Anthony Michael (Ledyard, CT), Gillmore; Adam (Sandwich, GB), Jones; Matthew Cameron (Sandwich, GB), Kougoulos; Eleftherios (Morrisville, NC), Luthra; Suman (Groton, CT), Walton; Robert (Sandwich, GB) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 15/833,073 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
More… ↓ |
Drugs Protected by US Patent 10,278,974
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 10,278,974 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 10,278,974 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 10,278,974 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,278,974
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2534153 | ⤷ Subscribe | 300958 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2534153 | ⤷ Subscribe | CA 2018 00041 | Denmark | ⤷ Subscribe |
| European Patent Office | 2534153 | ⤷ Subscribe | 122018000131 | Germany | ⤷ Subscribe |
| European Patent Office | 2534153 | ⤷ Subscribe | PA2018517 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2534153 | ⤷ Subscribe | LUC00093 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2534153 | ⤷ Subscribe | 2018C/044 | Belgium | ⤷ Subscribe |
| European Patent Office | 2534153 | ⤷ Subscribe | 48/2018 | Austria | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
